ClinicalTrials.gg
RecruitingNCT05063955MUSCLE-CHFUpdated Dec 26, 2023

Mechanism of Sarcopenia in Heart Failure

An observational study in Heart Failure, Sarcopenia and Cachexia, sponsored by Aarhus University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by Aarhus University Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.

Planned enrollment
25th of 54
250 · median 213
Started
2020
with 12 others
Observational
54 of 242
19 open now
Primary completion
2026-12
later than 22 of 59 live
Registered
164th of 242
by date

Among the 242 studies in Heart Failure with a site in Denmark, this one is the 25th largest by planned enrollment of the 54 observational ones that give a count, is one of 13 that started in 2020, is one of 54 observational ones, reaches primary completion later than 22 of the 59 other live ones, and was the 164th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 242 studies in Heart Failure with a site in Denmark, or all of them as a file.
02

Study summary

The aim of the study is to provide information on the interaction between socioeconomic factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle function in patients with heart failure.

Read the detailed description

A total of 200 consecutive heart failure patients will be included and 50 age and sex-matched individuals with no history of cardiovascular disease will serve as controls.

Baseline variables of body composition, physical capacity, daily physical activity, nutritional status, quality of life, socioeconomic status and insulin resistance will be obtained along with a skeletal muscle tissue biopsy and blood samples for laboratory analyses.

Baseline variables from heart failure patients will be compared to healthy controls.

Patients and controls will be invited to follow-up visits at 12 and 36 months. Changes in baseline variables will be analyzed.

Events will be identified through national registries.

03

Conditions studied

  • Heart Failure
  • Sarcopenia
  • Cachexia

Keywords

  • Heart failure
  • Sarcopenia
  • Cachexia
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A total of 200 consecutive heart failure patients will be included and 50 age and sex matched individuals with no history of cardiovascular disease will serve as controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide valid .
  2. Heart failure with preserved, mid-range or reduced ( I-IV) according to European Society of Cardiology guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Cancer requiring treatment (e.g. prostate cancer on watchful waiting does not exclude patients).
  2. Severe musculoskeletal or neurological disability.
  3. Severe lung disease with a forced expiratory volume 1 \< 40% of predicted. Treatment with anticoagulants (warfarin, apixaban, edoxaban, dabigatran and rivaroxaban) is an exclusion criterion for muscle . Patients with anticoagulant treatment will be invited to participate in the study without muscle biopsy.
  4. Other comorbidities that prevent the patient from participating in the study examinations as judged by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Chronic Heart Failure

    Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.

  • Controls

    Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.

06

What researchers measure

Primary outcomes

  1. Physical performance, peak VO2

    Change in peak oxygen uptake (peak VO2), measured in ml O2/kg/min

    Time frame: From baseline to 12 and 36 months

  2. Physical performance, walking distance

    Change in walking distance (6MWT) in meters

    Time frame: From baseline to 12 and 36 months

  3. Physical performance, muscle strength

    Change in knee extension/flexion isokinetic strength (assessed by peak torque, Nm) and isometric strength (assessed by peak torque, Nm)

    Time frame: From baseline to 12 and 36 months

Secondary outcomes

  1. Cardiovascular events

    Incidence of a composite endpoint of death, hospitalization with worsening of heart failure other cardiovascular events (myocardial infarction, unstable angina, revascularization and stroke) and non-cardiovascular hospitalizations

    Time frame: During follow-up of 10 years

  2. Body composition

    Change in appendicular lean mass (measured in grams) and fat mass (measured in grams)

    Time frame: From baseline to 12 and 36 months

  3. Muscle tissue fiber types

    Change in ratio between muscle fiber types (type I, IIa and IIb) assessed by immunohistochemistry

    Time frame: From baseline to 12 and 36 months

  4. Muscle tissue cellular composition

    Change in muscle tissue cellular composition assessed by cell sorting

    Time frame: From baseline to 12 and 36 months

  5. Muscle tissue mitochondrial function

    Change in muscle mitochondrial function assessed by high-resolution respirometry

    Time frame: From baseline to 12 and 36 months

  6. Daily physical activity

    Change in daily physical activity assessed by 7-day accelerometry

    Time frame: From baseline to 12 and 36 months

  7. Insulin resistance

    Changes in insulin resistance assessed by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    Time frame: From baseline to 12 and 36 months

  8. Whole body metabolism

    Changes in circulating metabolic markers

    Time frame: From baseline to 12 and 36 months

  9. Muscle metabolism

    Changes in metabolic signature of muscle tissue assessed by liquid chromatography-high-resolution mass spectrometry

    Time frame: From baseline to 12 and 36 months

  10. Symptoms

    Changes in the Minnesota Living with Heart Failure Questionnaire score (range 0-105, from best to worst)

    Time frame: From baseline to 12 and 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 72 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 72 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Oct 1, 2021
StartActual
Dec 2, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2033
Last update
Dec 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05063955
Responsible party
Henrik Wiggers (Professor, Aarhus University Hospital) — Principal investigator
First posted
Oct 1, 2021
Start date
Dec 2, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Dec 26, 2023

Study contacts

Henrik Wiggers, Prof.
Contact
henrikwiggers@dadlnet.dk
+45 2275 3202
Andreas B Tinggaard, MD
Contact
andreas.bugge@midt.rm.dk
+45 3027 2717
Henrik Wiggers, Prof.
study chair · Aarhus University Hospital
Andreas B Tinggaard, MD
study chair · Aarhus University Hospital
Søren P Johnsen, Prof.
study chair · Aalborg University Hospital
Helene Nørrelund, Ass. Prof.
study chair · Aarhus University Hospital
Anders H Larsen, MD, PhD
study chair · Aarhus University Hospital
Peter Leutscher, Prof.
study chair · Regionshospital Nordjylland
Peter B Stæhr, MD, PhD
study chair · Regionshospital Nordjylland
Steen H Jørgensen, MD
study chair · Regionshospital Nordjylland
Niels Jessen, Prof.
study chair · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion